pozen inc (POZN:NASDAQ GS)
pozen inc (POZN) Snapshot
|
Open
$5.00
|
Previous Close
$4.96
|
|
|
Day High
$5.08
|
Day Low
$4.90
|
|
|
52 Week High
06/20/12 - $7.55
|
52 Week Low
05/8/13 - $4.26
|
|
|
Market Cap
150.6M
|
Average Volume 10 Days
263.3K
|
|
|
EPS TTM
$-0.75
|
Shares Outstanding
30.4M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
pozen inc (POZN) Related Businessweek News
No Related Businessweek News Foundpozen inc (POZN) Details
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States. The company’s products include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. The company also provides PA32540 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and with AstraZeneca AB for the development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.
pozen inc (POZN) Top Compensated Officers
pozen inc (POZN) Key Developments
POZEN Inc. reported unaudited earnings results for the first quarter ended March 31, 2013. For the period, the company reported royalty revenue of $1,415,000 against $1,289,000 a year ago. Loss before income tax benefit was $5,777,932 against $8,394,732 a year ago. Net loss attributable to common stockholders was $5,777,932 or $0.19 per basic and diluted share against $8,394,732 or $0.28 per basic and diluted share a year ago.
POZEN Inc. announced that they will report Q1, 2013 results Pre-Market on May 08, 2013
POZEN Inc., Q1 2013 Earnings Call, May 08, 2013
| Recently Viewed | |||
| POZN:US | $4.96 USD | 0.00 |  |
| Company | Last | Change |
| BioDelivery Sciences International Inc | $4.34 USD | -0.19 |
| EpiCept Corp | $0.06 USD | +0.002 |
| Horizon Pharma Inc | $2.38 USD | -0.01 |
| Pain Therapeutics Inc | $3.08 USD | +0.07 |
| Sunesis Pharmaceuticals Inc | $5.61 USD | +0.09 |
| View Industry Companies | ||
Industry Analysis
POZN
Industry Average
| Valuation | POZN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 27.5x |
|
| Price/Book | 1.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 12.9x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
